Drug intelligence / Profile preview

MAX-2

Development stage: Unknown
Lead developer: Guangzhou Zaiji Medical Technology
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MAX-2 is a small molecule radiopharmaceutical imaging agent developed by **Guangzhou Zaiji Medical Technology** (Maxinovel) for use in positron emission tomography (PET) imaging. It is designed to target **Programmed cell death 1 ligand 1 (PD-L1)**, allowing for the non-invasive assessment of PD-L1 expression levels in patients with **solid tumors**. This imaging tool is intended to help clinicians identify patients who are most likely to benefit from PD-1/PD-L1 targeted immunotherapies and to monitor treatment response. MAX-2 is currently in **Phase 1/2** clinical development.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on MAX-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX-2.

Explore the full profile